SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

SEARCH BY NAME

BROWSE

Browse Australian listed companies0-9A BC DE FGH IJ KL MN OP QR ST UV WX YZ
Browse current Australian managed funds0-9A BCDE FGH IJKL MNOP QRST UVWX YZ

SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

ALCHEMIA LIMITED (ACL)

Listed on ASX ( $        )

SHARE PRICES

Former (or subsequent) names

 

Shareholder links

Our website ranking of ACL: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Link Market Services,Level 21, 10 Eagle Street Brisbane QLD 4000

Tel : +61 7 3320 2200 or 1300 554 474
Fax : +61 2 9287 0303
RegistryWebsite RegistryEmail

Company details

Address: Level 4 100 Albert Road South Melbourne VIC 3205
Tel:  +61 3 9692 7222 Fax: +61 3 3 9077 9233

Date first listed: 23/12/2003
Company Secretary: Melanie Leydin
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Development of carbohydrate-based molecules for therapeutic applications
The suspension of trading in the securities of Alchemia Limited will be lifted immediately, following the receipt of additional information about the ongoing activities of the Company.16/06/2016
The company provides an update on company activities.16/06/2016
The company advises that the ASX has suspended trading of the Company's securities effective close of trading on Tuesday 14 June 2016 due to ASX's opinion that the Company is not in compliance with ASX Listing Rule 12.1. The Company has this morning provided a submission to the ASX to demonstrate its ongoing compliance with Chapter 12 and specifically 12.1 of the Listing Rules. The ASX is currently in the process of reviewing this submission.15/06/2016
The securities ofAlchemia Limited (the "Company")will be suspended from quotation at the close oftrading today, Tuesday, 14 June 2016 in accordance with listing rule 17.3, as ASX has determined that the Company does not have sufficient operations to warrant the continued quotation of its securities in accordance with listing rule 12.1. The suspension will continue until either the Company is able to demonstrate compliance with Chapter 12 of the Listing Rules, or it complies with Chapters 1 and 2 of the Listing Rules.14/06/2016
we understand that on or about this date the company made a capital return of 9.3 cents per share01/02/2016
The suspension of trading in the securities of Alchemia Limited (the "Company") will be lifted immediately, following receipt of an announcement regarding the Company's profit share on sales of its generic anti-coagulant drug fondaparinux for the quarter ending 31 March 2015. Security Code: ACL29/05/2015
The company releases its Fondaparinux Result for Quarter Ended 31 March 2015.29/05/2015
The securities of Alchemia Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement regarding its profit share on sales of its generic anti-coagulant drug fondaparinux for the quarter ending 31 March 2015. Security Code: ACL26/05/2015
The suspension of trading in the securities of Alchemia Limited (the "Company") will be lifted immediately, following the Company" update in relation to the proposed demerger of Audeo Oncology, Inc. from the Company. Security Code: ACL21/12/2012
The securities of Alchemia Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, whilst it continues negotiations relating to the demerger of Audeo Oncology, Inc. from the Company. Security Code: ACL Adrian Smythe17/12/2012
we understand that on or about this date the company undertook, proposed to undertake or was the subject of the following corporate action: - demerge its wholly owned subsidiary Alchemia Oncology Pty Ltd - this corporate event may appear elsewhere in this company record18/10/2012

ASX Announcements (courtesy of ASX)

 

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    Posting your comments. Please wait...


    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    08/01/2018David Lamm-48,550,000 $0.016$798,309
    04/01/2018Darren Book-256,659 $0.021$5,447
    30/06/2017Darren Book1,000,000 $0.008$8,000
    12/03/2013Mel Bridges53,750 $0.370$19,888
    25/11/2011Mel Bridges94,000 $0.320$30,042

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Simon GennariNon Exec Chairman29/02/2016
    Melanie LeydinCFO11/04/2016
    David LammNon Exec Director07/03/2016
    Darren BookNon Exec Director12/12/2016

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Nathan DronaNon Exec Director22/03/201325/11/2016
    Tracie RamsdaleNon Exec Director26/04/200729/06/2016
    Jenni PilcherCFO01/09/201411/04/2016
    Ken PoutakidisNon Exec Chairman26/06/201529/02/2016
    Timothy HughesChairman15/07/201309/07/2015
    Santo CostaNon Exec Chairman01/03/201410/06/2015
    Susan KelleyNon Exec Director22/03/201310/06/2015
    Thomas LiquardCEO16/12/201311/11/2014
    Charles WalkerCEO24/02/2014
    Mel BridgesNon Exec Chairman15/07/2013
    Nerolie WithnallDirector27/10/200304/07/2013
    Peter SmithCEO26/04/200725/01/2013

    Date of first appointment, title may have changed.